Bemnifosbuvir Identified as Active Against Hepatitis E in Preclinical Report

A preclinical screen reported that bemnifosbuvir emerged as a candidate active against hepatitis E virus (HEV). In the report, investigators filtered this nucleotide/nucleoside analogue from a commercially available library of roughly 500 compounds by testing them against an HEV reporter virus carrying a fluorescent marker. The approach is described as tracking whether viral replication continued after candidate compounds were added to infected cell cultures.

In the in vitro experiments, HEV replication was tracked via the fluorescent signal generated by the reporter-virus system, with fluorescence serving as the readout for ongoing replication. In this assay, bemnifosbuvir was observed such that the virus no longer replicated. The report also notes a cell-culture observation: treated cells “remained healthy” while the replication signal was no longer seen. Together, the description pairs a reporter readout consistent with inhibited replication with a qualitative cell-health observation in that assay context.

The report then describes separate animal experiments, stating that these studies “confirmed” efficacy of the compound against HEV and also referencing liver inflammation as part of what was assessed. As reported, the animal findings are presented as confirmation within preclinical models, including reference to liver inflammation.

The report also situates bemnifosbuvir in a broader development and public health context. It describes the compound as a nucleotide/nucleoside analogue already recognized for activity against hepatitis C virus and notes that it is in ongoing clinical trials for hepatitis C. The report adds that there are currently neither licensed antivirals nor widely used vaccines for HEV. In that setting, the authors say that if the hepatitis C clinical trials are successful, the drug could become available for off-label use against hepatitis E as a forward-looking possibility, presented as contingent rather than as an outcome.